Biotech & Medicine
Engineered organ-donor animals
Transgenic animals bred as living organ farms, carrying human-compatible tissue that can be harvested repeatedly for transplant.
In shortEngineered organ-donor animals, from Oryx and Crake (Margaret Atwood, 2003), is at technology readiness level 5 of 9 (validated in relevant environment) at its weakest link. Held back by Somatic cell nuclear transfer cloning and Durable transplant immune tolerance. Science status: underlying science well understood; an engineering problem. Estimated new funding to unlock: $6.2B–21B.
Pigoons are pigs engineered with multiple human-tissue organ foldouts so that several transplantable organs grow in each animal, bred at OrganInc Farms and eventually feral and dangerous.
Closest todayGene-edited pig kidneys entered formal clinical trials in late 2025 (10-edit UKidney at NYU Langone, 69-edit EGEN-2784 cleared by FDA); the longest functioning pig kidney in a human lasted 271 days.
Dependency stack
Research TRL 1–3Development TRL 4–6Deployment TRL 7–9
Sort by
- Grafts currently fail to chronic rejection within months despite heavy immunosuppression
- Chronic antibody-mediated rejection proceeds even under current immunosuppression
- Tolerance protocols trade rejection risk for conditioning toxicity and graft-versus-host disease
- No assay predicts which recipients can be safely weaned off drugs
TRL 5 - The donor herd itself - edited, cloned, pathogen-free and transplant-qualified - is the technology
✕4 blockers›
- Graft survival measured in months, not years - chronic rejection and thrombotic microangiopathy persist
- Porcine endogenous retrovirus and novel-zoonosis risk requires lifelong recipient surveillance
- Organ growth mismatch and porcine protein incompatibilities (complement, coagulation) are only partly corrected by current edit sets
- Designated-pathogen-free breeding and organ-recovery facilities do not exist at transplant-program scale
TRL 6- Somatic cell nuclear transfer cloningbottleneckEdited cell lines are turned into animals by cloning
- Incomplete epigenetic reprogramming of the donor nucleus produces placental defects and large-offspring syndrome
- Efficiency is a few percent of transferred embryos, so each live birth consumes many donor eggs and surrogates
- Donor egg supply is the limiting input for any primate-scale program
TRL 5 - Even heavily edited organs are rejected without durable toleranceTRL 5
- Donor lines need tens of simultaneous edits across rejection, coagulation and retroviral loci
✕3 blockers›
- Structural variants and large deletions accumulate with edit count and are missed by short-read screening
- Edited cell lines lose clonogenic and developmental potency after many rounds of editing
- No method reaches the thousands of edits implied by whole-genome rewriting
TRL 6- Higher-fidelity, smaller editor and recombinase proteins are the route to many simultaneous edits
✕1 blocker›
- Designing catalysis and conformational dynamics
TRL 6
- Edited founder lines are propagated as cloned animalsTRL 5
- Dozens of edits are needed across antigen, complement, coagulation and retroviral lociTRL 6
- Growing extra human-tissue organs inside a host animal is tissue engineering with the animal as the bioreactor
✕4 blockers›
- Capillary-scale perfusion cannot be printed and must self-assemble, which is uncontrolled today
- Printed tissue must mature into function (filtration, metabolism, contraction), and maturation protocols stall at fetal-like performance
- Cell demand of 10^10-10^11 per organ exceeds current manufacturing
- Mechanical integration - ureters, bile ducts, valves - has no demonstrated fabrication route
TRL 4- Without a capillary network, tissue thicker than a few hundred microns dies
✕3 blockers›
- Printing resolution stops at tens of microns while capillaries are 5-10 microns, so the smallest and most numerous vessels must self-assemble
- Engineered endothelium is thrombogenic, so perfused constructs clot
- No method guides anastomosis of a construct's vasculature to host vessels at scale
TRL 3 - Banked-cell organs are not patient-matched, so acceptance must be engineeredTRL 5
- One organ needs 10^10-10^11 clinical-grade cells of several types
✕3 blockers›
- Genomic instability and drift accumulate over the expansion needed for 10^11 cells
- Each organ needs many cell types differentiated on a synchronized schedule, not one lineage
- Cost per cell at current media and reagent prices makes a printed organ unaffordable
TRL 6
Who could unlock it
- Across several requirements:
- Colossal Biosciences 2
- Tatsuo Kawai 2
- eGenesis 2
Somatic cell nuclear transfer cloningTRL 5bottleneck
- Qiang SunResearcher, Institute of Neuroscience, Chinese Academy of SciencesCloned the macaques Zhong Zhong and Hua Hua (2018) and ReTro, the first cloned rhesus to reach adulthood, using trophoblast replacement (2024)
- Institute of Neuroscience, Chinese Academy of SciencesGovernment labThe only group to have produced primate clones; its 2024 result consumed 113 transferred embryos for one surviving animal
- ViaGen Pets and EquineCompanyThe commercial SCNT operation, cloning cats, dogs and horses and the Przewalski's horse Kurt; acquired by Colossal Biosciences in November 2025
- Colossal BiosciencesStartupUses cloning from edited cell lines as its route to live animals and bought ViaGen in 2025 to bring that throughput in-house
Durable transplant immune toleranceTRL 5bottleneck
- Medeor TherapeuticsStartupIts Phase 3 MDR-101 trial left 15 of 20 HLA-matched living-donor kidney recipients functionally tolerant and off all immunosuppression two years after withdrawal, with no graft loss or GVHD (Am J Transplant, 2025)
- Dixon KaufmanResearcher, University of Wisconsin-MadisonFirst author of the MDR-101 Phase 3 report (2025), the first randomised controlled demonstration of durable drug-free tolerance in kidney transplantation
- Megan SykesResearcher, Columbia Center for Translational ImmunologyPioneered minimal-conditioning mixed chimerism and xenogeneic thymic transplantation for tolerance; awarded the 2025 Starzl Prize for the path to xenograft tolerance
- Tatsuo KawaiResearcher, Legorreta Center for Clinical Transplant Tolerance, Massachusetts General HospitalRuns the combined kidney and bone-marrow tolerance protocols across HLA barriers and operated on the 2025 engineered-porcine-kidney recipients
Gene-edited xenograft donor animalsTRL 6
- United Therapeutics (Revivicor)CompanyIts 10-edit UKidney entered the EXPAND trial at NYU Langone in November 2025; it is building designated-pathogen-free herds, including a $110M facility in Stewartville, Minnesota due to operate in 2027, toward thousands of organs a year
- eGenesisStartupGot FDA IND clearance for the 69-edit EGEN-2784 kidney in September 2025; its expanded-access recipient passed seven months dialysis-free, the longest survival with an engineered porcine organ
- David AyaresResearcher, Revivicor, United TherapeuticsMade the original alpha-gal knockout pigs and the multi-edit donor lines used in nearly every US xenotransplant to date
- Robert MontgomeryResearcher, NYU Langone Transplant InstitutePerformed the first decedent xenokidney transplants (2021) and led the first transplant in the EXPAND clinical trial (November 2025)
Multiplex genome engineeringTRL 6
- eGenesisStartupIts 69-edit Yucatan miniature pigs supply clinical xenotransplants; a kidney from one functioned 271 days in a patient, reported September 2026
- Colossal BiosciencesStartupMade eight simultaneous edits across seven genes in its woolly mouse (March 2025) and 20 edits at 14 loci in a gray wolf cell line
- George ChurchResearcher, Harvard Medical School and Wyss InstituteOriginated multiplex genome engineering and co-founded both eGenesis and Colossal; the 2025 woolly mouse work used his lab's multiplexing toolset
- RevivicorCompanyUnited Therapeutics subsidiary whose 10-edit pigs produced the first gene-edited pig heart transplants and now supply FDA-cleared xenotransplant trials
Beyond engineering
- Zoonosis surveillance obligations on recipients for life
- Animal welfare limits on multi-organ engineered donors
- Allocation and pricing of a manufactured organ supply